Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30053663HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30020614HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053664HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053665HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053666HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053667HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053668HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053669HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053670HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30053671HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TCGA Plot Options
Drug Information
GeneTOP1
DrugBank IDDB14962
Drug NameTrastuzumab deruxtecan
Target IDBE0000971
UniProt IDP11387
Regulation Typeinhibitor
PubMed IDs31047803
CitationsTamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S: Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL